R&D News | pharmaphorum

News

Roche is paying $75m upfront for a trispecific drug developed by China's Simcere Zaiming for B-cell-mediated autoimmune disorders and blood cancers.

News

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.

News

Buoyed by positive data in a phase 2 trial, GSK will start a phase 3 programme for an mRNA-based flu shot targeting both HA and NA flu antigens.

News

Novartis stops eight trials of CAR-T rap-cel in autoimmune diseases after three deaths, with BMS also halting studies of zola-cel as a precaution.

News

Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at ESC 2026.

News

An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients with heart failure.